Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Insulin dosing guidance to optimise type 2 diabetes management - Authors' reply.

Bergenstal RM, Johnson ML, Bashan E, Hodish I.

Lancet. 2019 Oct 12;394(10206):1321. doi: 10.1016/S0140-6736(19)31895-1. No abstract available.

PMID:
31609220
2.

Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.

Monteiro P, Bergenstal RM, Toural E, Inzucchi SE, Zinman B, Hantel S, Kiš SG, Kaspers S, George JT, Fitchett D; EMPA-REG OUTCOME® Investigators.

Age Ageing. 2019 Oct 3. pii: afz096. doi: 10.1093/ageing/afz096. [Epub ahead of print]

PMID:
31579904
3.

Advances in technology for management of type 1 diabetes.

Beck RW, Bergenstal RM, Laffel LM, Pickup JC.

Lancet. 2019 Oct 5;394(10205):1265-1273. doi: 10.1016/S0140-6736(19)31142-0. Epub 2019 Sep 15. Review.

PMID:
31533908
4.

Emphasizing Optimal Diabetes Management for All Races/Ethnicities, but Not Race/Ethnicity-Specific Cut Points for Hemoglobin A1c.

Bergenstal RM, Beck RW.

JAMA Ophthalmol. 2019 Aug 22. doi: 10.1001/jamaophthalmol.2019.3233. [Epub ahead of print] No abstract available.

PMID:
31436784
5.

Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring.

Larkin ME, Nathan DM, Bebu I, Krause-Steinrauf H, Herman WH, Higgins JM, Tiktin M, Cohen RM, Lund C, Bergenstal RM, Johnson ML, Arends V; GRADE Research Group.

Diabetes Technol Ther. 2019 Sep 4. doi: 10.1089/dia.2019.0202. [Epub ahead of print]

PMID:
31393176
6.

Advanced Technology in the Management of Diabetes: Which Comes First-Continuous Glucose Monitor or Insulin Pump?

Martin CT, Criego AB, Carlson AL, Bergenstal RM.

Curr Diab Rep. 2019 Jun 27;19(8):50. doi: 10.1007/s11892-019-1177-7. Review.

7.

Young Children Have Higher Variability of Insulin Requirements: Observations During Hybrid Closed-Loop Insulin Delivery.

Dovc K, Boughton C, Tauschmann M, Thabit H, Bally L, Allen JM, Acerini CL, Arnolds S, de Beaufort C, Bergenstal RM, Campbell F, Criego A, Dunger DB, Elleri D, Evans ML, Fröhlich-Reiterer E, Hofer S, Kapellen T, Leelarathna L, Pieber TR, Rami-Merhar B, Shah VN, Sibayan J, Wilinska ME, Hovorka R; APCam11, AP@Home, and KidsAP Consortia.

Diabetes Care. 2019 Jul;42(7):1344-1347. doi: 10.2337/dc18-2625. Epub 2019 May 21.

PMID:
31221700
8.

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.

Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ 3rd, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Nørgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M.

Diabetes Care. 2019 Aug;42(8):1593-1603. doi: 10.2337/dci19-0028. Epub 2019 Jun 8. Review.

9.

Utilizing the Ambulatory Glucose Profile to Standardize and Implement Continuous Glucose Monitoring in Clinical Practice.

Johnson ML, Martens TW, Criego AB, Carlson AL, Simonson GD, Bergenstal RM.

Diabetes Technol Ther. 2019 Jun;21(S2):S217-S225. doi: 10.1089/dia.2019.0034.

PMID:
31169432
10.

Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen.

Bergenstal RM, Peyrot M, Dreon DM, Aroda VR, Bailey TS, Brazg RL, Frias JP, Johnson ML, Klonoff DC, Kruger DF, Ramtoola S, Rosenstock J, Serusclat P, Weinstock RS, Naik RG, Shearer DM, Zraick V, Levy BL; Calibra Study Group.

Diabetes Technol Ther. 2019 May;21(5):273-285. doi: 10.1089/dia.2018.0298. Epub 2019 Apr 26.

11.

EVALUATION OF INSULIN GLARGINE AND EXENATIDE ALONE AND IN COMBINATION: A RANDOMIZED CLINICAL TRIAL WITH CONTINUOUS GLUCOSE MONITORING AND AMBULATORY GLUCOSE PROFILE ANALYSIS.

Carlson AL, Mullen DM, Mazze R, Strock E, Richter S, Bergenstal RM.

Endocr Pract. 2019 Apr;25(4):306-314. doi: 10.4158/EP-2018-0177.

PMID:
30995433
12.

Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring.

Pettus J, Gill J, Paranjape S, Stewart J, Malla S, Edelman S, Bergenstal RM, Bode B.

Diabetes Obes Metab. 2019 Aug;21(8):1906-1913. doi: 10.1111/dom.13751. Epub 2019 May 9.

PMID:
30993855
13.

Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial.

Bergenstal RM, Johnson M, Passi R, Bhargava A, Young N, Kruger DF, Bashan E, Bisgaier SG, Isaman DJM, Hodish I.

Lancet. 2019 Mar 16;393(10176):1138-1148. doi: 10.1016/S0140-6736(19)30368-X. Epub 2019 Feb 23.

PMID:
30808512
14.

Glucose Management Indicator (GMI): Insights and Validation Using Guardian 3 and Navigator 2 Sensor Data.

Leelarathna L, Beck RW, Bergenstal RM, Thabit H, Hovorka R; APCam11, AP@home04, and APCam08 Investigators.

Diabetes Care. 2019 Apr;42(4):e60-e61. doi: 10.2337/dc18-2479. Epub 2019 Feb 6. No abstract available.

PMID:
30728221
15.

The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c.

Beck RW, Bergenstal RM, Cheng P, Kollman C, Carlson AL, Johnson ML, Rodbard D.

J Diabetes Sci Technol. 2019 Jul;13(4):614-626. doi: 10.1177/1932296818822496. Epub 2019 Jan 13.

PMID:
30636519
16.

The Association of Biochemical Hypoglycemia with the Subsequent Risk of a Severe Hypoglycemic Event: Analysis of the DCCT Data Set.

Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C.

Diabetes Technol Ther. 2019 Jan;21(1):1-5. doi: 10.1089/dia.2018.0362. Epub 2018 Dec 21.

PMID:
30575408
17.

Response to Comment on Bergenstal et al. Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. Diabetes Care 2018;41:2275-2280.

Bergenstal RM, Beck RW, Close KL, Grunberger G, Sacks DB, Kowalski A, Brown AS, Heinemann L, Aleppo G, Ryan DB, Riddlesworth TD, Cefalu WT.

Diabetes Care. 2019 Feb;42(2):e29-e30. doi: 10.2337/dci18-0061. Epub 2018 Dec 17. No abstract available.

PMID:
30559104
18.

Approach to Using Trend Arrows in the FreeStyle Libre Flash Glucose Monitoring Systems in Adults.

Kudva YC, Ahmann AJ, Bergenstal RM, Gavin JR 3rd, Kruger DF, Midyett LK, Miller E, Harris DR.

J Endocr Soc. 2018 Nov 14;2(12):1320-1337. doi: 10.1210/js.2018-00294. eCollection 2018 Dec 1. Review.

19.

Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.

Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, Close KL.

Diabetes Care. 2019 Mar;42(3):400-405. doi: 10.2337/dc18-1444. Epub 2018 Oct 23.

PMID:
30352896
20.

Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.

Tauschmann M, Thabit H, Bally L, Allen JM, Hartnell S, Wilinska ME, Ruan Y, Sibayan J, Kollman C, Cheng P, Beck RW, Acerini CL, Evans ML, Dunger DB, Elleri D, Campbell F, Bergenstal RM, Criego A, Shah VN, Leelarathna L, Hovorka R; APCam11 Consortium.

Lancet. 2018 Oct 13;392(10155):1321-1329. doi: 10.1016/S0140-6736(18)31947-0. Epub 2018 Oct 3. Erratum in: Lancet. 2018 Oct 13;392(10155):1310.

21.

Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring.

Bergenstal RM, Beck RW, Close KL, Grunberger G, Sacks DB, Kowalski A, Brown AS, Heinemann L, Aleppo G, Ryan DB, Riddlesworth TD, Cefalu WT.

Diabetes Care. 2018 Nov;41(11):2275-2280. doi: 10.2337/dc18-1581. Epub 2018 Sep 17.

PMID:
30224348
22.

Identifying Trends in Undiagnosed Diabetes in U.S. Adults.

Selvin E, Wang D, Lee AK, Coresh J, Bergenstal RM.

Ann Intern Med. 2018 Jun 19;168(12):900-901. doi: 10.7326/L18-0098. No abstract available.

PMID:
29913500
23.

Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.

Cavender MA, White WB, Liu Y, Massaro JM, Bergenstal RM, Mehta CR, Zannad F, Heller S, Cushman WC, Cannon CP.

Clin Cardiol. 2018 Aug;41(8):1022-1027. doi: 10.1002/clc.22960. Epub 2018 Aug 16.

24.

Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.

White WB, Heller SR, Cannon CP, Howitt H, Khunti K, Bergenstal RM; EXAMINE Investigators.

Am J Med. 2018 Jul;131(7):813-819.e5. doi: 10.1016/j.amjmed.2018.02.023. Epub 2018 Mar 23.

PMID:
29581078
25.

Optimal Sampling Duration for Continuous Glucose Monitoring to Determine Long-Term Glycemic Control.

Riddlesworth TD, Beck RW, Gal RL, Connor CG, Bergenstal RM, Lee S, Willi SM.

Diabetes Technol Ther. 2018 Apr;20(4):314-316. doi: 10.1089/dia.2017.0455. Epub 2018 Mar 22.

PMID:
29565197
26.

Continuous glucose monitoring: transforming diabetes management step by step.

Bergenstal RM.

Lancet. 2018 Apr 7;391(10128):1334-1336. doi: 10.1016/S0140-6736(18)30290-3. Epub 2018 Feb 16. No abstract available.

PMID:
29459022
27.

Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A1c Levels.

Bergenstal RM, Gal RL, Beck RW.

Ann Intern Med. 2018 Feb 6;168(3):232-233. doi: 10.7326/L17-0589. No abstract available.

PMID:
29404586
28.

International Consensus on Use of Continuous Glucose Monitoring.

Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R, Bosi E, Buckingham B, Cobelli C, Dassau E, Doyle FJ 3rd, Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, Nørgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M.

Diabetes Care. 2017 Dec;40(12):1631-1640. doi: 10.2337/dc17-1600. Review.

29.

Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations: A Joint Statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group.

Petrie JR, Peters AL, Bergenstal RM, Holl RW, Fleming GA, Heinemann L.

Diabetes Care. 2017 Dec;40(12):1614-1621. doi: 10.2337/dci17-0043. Epub 2017 Oct 25. Review.

PMID:
29070577
30.

Improving the clinical value and utility of CGM systems: issues and recommendations : A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group.

Petrie JR, Peters AL, Bergenstal RM, Holl RW, Fleming GA, Heinemann L.

Diabetologia. 2017 Dec;60(12):2319-2328. doi: 10.1007/s00125-017-4463-4. Epub 2017 Oct 25. Review.

PMID:
29067486
31.

Response to Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care 2017;40:777-783.

Lachin JM, Bebu I, Bergenstal RM, Pop-Busui R, Service FJ, Zinman B, Nathan DM; DCCT/EDIC Research Group.

Diabetes Care. 2017 Nov;40(11):e165-e166. doi: 10.2337/dci17-0038. No abstract available.

32.

Identifying Trends in Undiagnosed Diabetes in U.S. Adults by Using a Confirmatory Definition: A Cross-sectional Study.

Selvin E, Wang D, Lee AK, Bergenstal RM, Coresh J.

Ann Intern Med. 2017 Dec 5;167(11):769-776. doi: 10.7326/M17-1272. Epub 2017 Oct 24.

33.

The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading.

Beck RW, Connor CG, Mullen DM, Wesley DM, Bergenstal RM.

Diabetes Care. 2017 Aug;40(8):994-999. doi: 10.2337/dc17-0636.

34.

Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial.

Beck RW, Riddlesworth TD, Ruedy KJ, Kollman C, Ahmann AJ, Bergenstal RM, Bhargava A, Bode BW, Haller S, Kruger DF, McGill JB, Polonsky W, Price D, Toschi E; DIAMOND Study Group.

Lancet Diabetes Endocrinol. 2017 Sep;5(9):700-708. doi: 10.1016/S2213-8587(17)30217-6. Epub 2017 Jul 12.

PMID:
28711468
35.

Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol.

Bally L, Thabit H, Tauschmann M, Allen JM, Hartnell S, Wilinska ME, Exall J, Huegel V, Sibayan J, Borgman S, Cheng P, Blackburn M, Lawton J, Elleri D, Leelarathna L, Acerini CL, Campbell F, Shah VN, Criego A, Evans ML, Dunger DB, Kollman C, Bergenstal RM, Hovorka R.

BMJ Open. 2017 Jul 13;7(7):e016738. doi: 10.1136/bmjopen-2017-016738.

36.

Evaluating Interventions and Titrations Using Fasting Blood Glucose.

Minor JM, Rickey LM, Bergenstal RM.

J Diabetes Sci Technol. 2018 Jan;12(1):226-227. doi: 10.1177/1932296817718340. Epub 2017 Jul 5. No abstract available.

37.

Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).

Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, Riddle MC.

Diabetes Obes Metab. 2018 Jan;20(1):121-128. doi: 10.1111/dom.13048. Epub 2017 Aug 8.

38.

Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.

Bolli GB, Riddle MC, Bergenstal RM, Wardecki M, Goyeau H, Home PD; EDITION 3 study investigators.

Diabetes Metab. 2017 Sep;43(4):351-358. doi: 10.1016/j.diabet.2017.04.007. Epub 2017 Jun 13.

39.

Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A1c Levels.

Bergenstal RM, Gal RL, Connor CG, Gubitosi-Klug R, Kruger D, Olson BA, Willi SM, Aleppo G, Weinstock RS, Wood J, Rickels M, DiMeglio LA, Bethin KE, Marcovina S, Tassopoulos A, Lee S, Massaro E, Bzdick S, Ichihara B, Markmann E, McGuigan P, Woerner S, Ecker M, Beck RW; T1D Exchange Racial Differences Study Group.

Ann Intern Med. 2017 Jul 18;167(2):95-102. doi: 10.7326/M16-2596. Epub 2017 Jun 13.

PMID:
28605777
40.

Clinical Use of Continuous Glucose Monitoring in Adults with Type 2 Diabetes.

Carlson AL, Mullen DM, Bergenstal RM.

Diabetes Technol Ther. 2017 May;19(S2):S4-S11. doi: 10.1089/dia.2017.0024. Review.

41.

Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972-1980.

Aroda VR, Rosenstock J, Wysham C, Unger J, Bellido D, González-Gálvez G, Takami A, Guo H, Niemoeller E, Souhami E, Bergenstal RM; LixiLan-L Trial Investigators.

Diabetes Care. 2017 Jun;40(6):809. doi: 10.2337/dc17-er06d. Epub 2017 Apr 20. No abstract available.

42.

Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial.

Lachin JM, Bebu I, Bergenstal RM, Pop-Busui R, Service FJ, Zinman B, Nathan DM; DCCT/EDIC Research Group.

Diabetes Care. 2017 Jun;40(6):777-783. doi: 10.2337/dc16-2426. Epub 2017 Apr 12.

43.

Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.

Wysham C, Bonadonna RC, Aroda VR, Puig Domingo M, Kapitza C, Stager W, Yu C, Niemoeller E, Souhami E, Bergenstal RM; LixiLan-L trial investigators.

Diabetes Obes Metab. 2017 Oct;19(10):1408-1415. doi: 10.1111/dom.12961. Epub 2017 Jun 8.

44.

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).

Russell-Jones D, Bode BW, De Block C, Franek E, Heller SR, Mathieu C, Philis-Tsimikas A, Rose L, Woo VC, Østerskov AB, Graungaard T, Bergenstal RM.

Diabetes Care. 2017 Jul;40(7):943-950. doi: 10.2337/dc16-1771. Epub 2017 Mar 29.

PMID:
28356319
45.

Digital Health Care by In Silico Glycation of HbA1 Blood Cells.

Minor JM, Rickey LM, Bergenstal RM.

J Diabetes Sci Technol. 2017 Sep;11(5):975-979. doi: 10.1177/1932296817700920. Epub 2017 Mar 22.

46.

REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes.

Aleppo G, Ruedy KJ, Riddlesworth TD, Kruger DF, Peters AL, Hirsch I, Bergenstal RM, Toschi E, Ahmann AJ, Shah VN, Rickels MR, Bode BW, Philis-Tsimikas A, Pop-Busui R, Rodriguez H, Eyth E, Bhargava A, Kollman C, Beck RW; REPLACE-BG Study Group.

Diabetes Care. 2017 Apr;40(4):538-545. doi: 10.2337/dc16-2482. Epub 2017 Feb 16.

47.

Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes.

Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, Brazg RL, Ilany J, Slover RH, Anderson SM, Bergenstal RM, Grosman B, Roy A, Cordero TL, Shin J, Lee SW, Kaufman FR.

Diabetes Technol Ther. 2017 Mar;19(3):155-163. doi: 10.1089/dia.2016.0421. Epub 2017 Jan 30.

48.

Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections.

Bergenstal RM, Bailey TS, Rodbard D, Ziemen M, Guo H, Muehlen-Bartmer I, Ahmann AJ.

Diabetes Care. 2017 Apr;40(4):554-560. doi: 10.2337/dc16-0684. Epub 2017 Jan 23.

PMID:
28115474
49.

Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.

Heller SR, Bergenstal RM, White WB, Kupfer S, Bakris GL, Cushman WC, Mehta CR, Nissen SE, Wilson CA, Zannad F, Liu Y, Gourlie NM, Cannon CP; EXAMINE Investigators.

Diabetes Obes Metab. 2017 May;19(5):664-671. doi: 10.1111/dom.12871. Epub 2017 Feb 27. Erratum in: Diabetes Obes Metab. 2017 Sep;19(9):1333.

50.

Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring.

Bergenstal RM, Strock E, Mazze R, Powers MA, Monk AM, Richter S, Souhami E, Ahrén B.

Diabetes Metab Res Rev. 2017 May;33(4). doi: 10.1002/dmrr.2879. Epub 2017 Feb 28.

PMID:
28032465

Supplemental Content

Loading ...
Support Center